Design of new α-glucosidase inhibitors based on the bis-4-hydroxycoumarin skeleton: Synthesis, evaluation, and in silico studies.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 Aug 2024
Historique:
received: 30 03 2024
accepted: 06 08 2024
medline: 13 8 2024
pubmed: 13 8 2024
entrez: 12 8 2024
Statut: epublish

Résumé

In this work, we have reported the design, synthesis, in vitro, and in silico enzymatic evaluation of new bis-4-hydroxycoumarin-based phenoxy-1,2,3-triazole-N-phenylacetamide derivatives 5a-m as potent α-glucosidase inhibitors. All the synthesized analogues showed high inhibition effects against α-glucosidase (IC

Identifiants

pubmed: 39134641
doi: 10.1038/s41598-024-69592-0
pii: 10.1038/s41598-024-69592-0
doi:

Substances chimiques

Glycoside Hydrolase Inhibitors 0
alpha-Glucosidases EC 3.2.1.20
4-Hydroxycoumarins 0
4-hydroxycoumarin X954ZLL2RD

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18693

Informations de copyright

© 2024. The Author(s).

Références

Barnard, K. D., Lloyd, C. E. & Holt, R. I. Psychological burden of diabetes and what it means to people with diabetes. In Psychology and diabetes care (eds Barnard, K. D. & Lloyd, C. E.) 1–22 (Springer, 2012).
doi: 10.1007/978-0-85729-573-6
Mukhtar, Y., Galalain, A. & Yunusa, U. A modern overview on diabetes mellitus: a chronic endocrine disorder. Eur. J. Biol. 5, 1–14 (2020).
doi: 10.47672/ejb.409
Ozougwu, J. C., Obimba, K. C., Belonwu, C. D. & Unakalamba, C. B. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J. Physiol. Pathophysiol. 4, 46–57 (2013).
doi: 10.5897/JPAP2013.0001
Mezza, T. et al. β-cell fate in human insulin resistance and type 2 diabetes: A perspective on islet plasticity. Diabetes 68, 1121–1129 (2019).
doi: 10.2337/db18-0856 pubmed: 31109941 pmcid: 6905483
Khan, H. M. S. et al. Evidence based study of side effects of drugs used in the treatment of diabetes mellitus. Afr. J. Pharm. Pharmacol. 6, 1805–1808 (2012).
Chaudhury, A. et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front. Endocrinol. 8, 6 (2017).
doi: 10.3389/fendo.2017.00006
Campbell, L. K., White, J. R. & Campbell, R. K. Acarbose: Its role in the treatment of diabetes mellitus. Ann. Pharmacother. 30, 1255–1262 (1996).
doi: 10.1177/106002809603001110 pubmed: 8913408
Riccardi, G. et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: A placebo-controlled, double-blind, multicentre study. Diabet Med. 16, 228–232 (1999).
doi: 10.1046/j.1464-5491.1999.00047.x pubmed: 10227568
Sohrabi, M. et al. A review on α-glucosidase inhibitory activity of first row transition metal complexes: A futuristic strategy for treatment of type 2 diabetes. RSC Adv. 12, 12011–12052 (2022).
doi: 10.1039/D2RA00067A pubmed: 35481063 pmcid: 9020348
Mushtaq, A., Azam, U., Mehreen, S. & Naseer, M. M. Synthetic α-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges. Eur. J. Med. Chem. 249, 115119 (2023).
doi: 10.1016/j.ejmech.2023.115119 pubmed: 36680985
Nelson, K. M. et al. The essential medicinal chemistry of curcumin. J. Med. Chem. 60, 1620–1637 (2017).
doi: 10.1021/acs.jmedchem.6b00975 pubmed: 28074653 pmcid: 5346970
Singh, A. et al. Recent developments in synthetic α-glucosidase inhibitors: A comprehensive review with structural and molecular insight. J. Mol. Struct. 1281, 135115 (2023).
doi: 10.1016/j.molstruc.2023.135115
Santos, C. M., Freitas, M. & Fernandes, E. A comprehensive review on xanthone derivatives as α-glucosidase inhibitors. Eur. J. Med. Chem. 157, 1460–1479 (2018).
doi: 10.1016/j.ejmech.2018.07.073 pubmed: 30282319
Rahim, F. et al. Isatin based Schiff bases as inhibitors of α-glucosidase: Synthesis, characterization, in vitro evaluation and molecular docking studies. Bioorg. Chem. 60, 42–48 (2015).
doi: 10.1016/j.bioorg.2015.03.005 pubmed: 25955493
Ullah, W. et al. Synthesis of indole based sulfonamide derivatives as potent inhibitors of α-glucosidase and α-amylase in management of type-II diabetes. Chem. Data Coll. 50, 101122 (2024).
Rahim, F. et al. Thiadiazole based triazole/hydrazone derivatives: Synthesis, in vitro α-glucosidase inhibitory activity and in silico molecular docking study. J. Mol. Struct. 1287, 135619 (2023).
doi: 10.1016/j.molstruc.2023.135619
Khan, S. et al. Synthesis, in vitro biological assessment, and molecular docking study of benzimidazole-based thiadiazole derivatives as dual inhibitors of α-amylase and α-glucosidase. Front. Chem. 11, 1125915 (2023).
doi: 10.3389/fchem.2023.1125915 pubmed: 37214481 pmcid: 10196468
Hayat, S. et al. Synthesis, biological evaluation and molecular docking study of benzimidazole derivatives as α-glucosidase inhibitors and anti-diabetes candidates. J. Mol. Struct. 1276, 134774 (2023).
doi: 10.1016/j.molstruc.2022.134774
Rashid, U. et al. Synthesis of 2-acylated and sulfonated 4-hydroxycoumarins: in vitro urease inhibition and molecular docking studies. Bioorg. Chem. 66, 111–116 (2016).
doi: 10.1016/j.bioorg.2016.04.005 pubmed: 27140727
Tafesse, T. B. et al. Coumarin-based scaffold as α-glucosidase inhibitory activity: Implication for the development of potent antidiabetic agents. Mini-Rev. Med. Chem. 20, 134–151 (2020).
doi: 10.2174/1389557519666190925162536 pubmed: 31553294
Ranđelović, S. & Bipat, R. A review of coumarins and coumarin-related compounds for their potential antidiabetic effect. Clin. Med. Insights: Endocrinol. Diabetes. 14, 11795514211042024 (2021).
pubmed: 35173509
Mohammadi-Khanaposhtani, M. et al. New biscoumarin derivatives as potent α-glucosidase inhibitors: Synthesis, biological evaluation, kinetic analysis, and docking study. Polycycl. Aromat. Compd. 40, 915–926 (2020).
doi: 10.1080/10406638.2018.1509359
Khan, K. M. et al. Synthesis and molecular docking studies of potent α-glucosidase inhibitors based on biscoumarin skeleton. Eur. J. Med. Chem. 81, 245–252 (2014).
doi: 10.1016/j.ejmech.2014.05.010 pubmed: 24844449
Ibrahim, M. T., Uzairu, A., Shallangwa, G. A. & Ibrahim, A. Computational studies of some biscoumarin and biscoumarin thiourea derivatives as alfa-glucosidase inhibitors. J. Eng. Exact Sci. 4, 0276–0285 (2018).
doi: 10.18540/jcecvl4iss2pp0276-0285
Zawawi, N. K. et al. Synthesis, in vitro evaluation and molecular docking studies of biscoumarin thiourea as a new inhibitor of α-glucosidases. Bioorg. Chem. 63, 36–44 (2015).
doi: 10.1016/j.bioorg.2015.09.004 pubmed: 26432614
Asgari, M. S. et al. Biscoumarin-1, 2, 3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies. Bioorg. Chem. 92, 103206 (2019).
doi: 10.1016/j.bioorg.2019.103206 pubmed: 31445191
Noori, M. et al. Design, synthesis, in vitro, and in silico enzymatic evaluations of thieno [2, 3-b] quinoline-hydrazones as novel inhibitors for α-glucosidase. Bioorg. Chem. 127, 105996 (2022).
doi: 10.1016/j.bioorg.2022.105996 pubmed: 35878449
Seul, S. C. Bioinformatics and Molecular Design Research Center. PreADMET program. Available from http://preadmet.bmdrc.org (2004).

Auteurs

Zahra Soleimani (Z)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Mohammadi (M)

Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Halimi (M)

Department of Biology, Babol Branch, Islamic Azad University, Babol, Iran.

Sajedeh Safapoor (S)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Navid Dastyafteh (N)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Elham Safaie (E)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Somayeh Mojtabavi (S)

Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Ali Faramarzi (MA)

Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Bozorgi-Koushalshahi (M)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Bagher Larijani (B)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Mohammadi-Khanaposhtani (M)

Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. maryammoha@gmail.com.

Mohammad Mahdavi (M)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. momahdavi@tums.ac.ir.

Articles similaires

Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria
Animals Hemiptera Insect Proteins Phylogeny Insecticides
Humans Meta-Analysis as Topic Sample Size Models, Statistical Computer Simulation
Alzheimer Disease Humans Regression Analysis Quantitative Structure-Activity Relationship Drug Design

Classifications MeSH